Associated Papers
PPP2R1A mutations portend improved survival after cancer immunotherapy.
Dai Y et al.
Nature, 2025
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A et al.
Cancer Medicine, 2021
33314633 (PubMed )
Supplement: CAM4-10-53-s004.xlsx › Sheet1
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Haesen D et al.
Cancer Research, 2016
CanDrA: cancer-specific driver missense mutation annotation with optimized features.
Mao Y et al.
Plos One, 2013
24205039 (PubMed )
Supplement: pone.0077945.s001.xls › Table_S10
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK et al.
The Journal of Pathology, 2011
Select a paper to view details